EU Takes Action To Prevent Further Impurities After Sartans
Executive Summary
The EMA is launching an initiative aimed at preventing impurities in medicines and better handling cases where impurities do occur, following the agency’s experiences in dealing with sartans that contained nitrosamine impurities.
You may also be interested in...
Sartans Recalled In UK As Further Impurity Is Confirmed
Certain batches of two angiotensin II receptor blockers, or sartans, are being recalled in the UK after an impurity that can potentially increase the risk of cancer over time was detected.
Sartans Recalled In UK As Further Impurity Is Confirmed
Certain batches of two angiotensin II receptor blockers, or sartans, are being recalled in the UK after an impurity that can potentially increase the risk of cancer over time was detected.
EU Takes Lessons From Valsartan Crisis
EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.